Safety, Tolerability and Pharmacodynamics of SHR-1707 in Alzheimer's Disease Patients.
- Disease/Condition
- Alzheimer's Disease
- Drug/Device/Intervention
- SHR-1707
- Study type
- Interventional
- Intervention type
- drug
- Primary sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- Phase
- Phase 1
- Start date
- Feb 20, 2023
- End date
- Aug 18, 2025
- Enrollment
- 41 participants
To assess the number of patients with adverse events (AEs),To assess the number of patients with clinically significant change from baseline in vital signs values,,To assess the number of patients with clinically significant change in physical examination,,To assess the number of patients with clinically significant change from baseline in laboratory examination,,To assess the number of patients with clinically significant change from baseline in 12-ECG values,,To assess the number of patients with clinically significant change in brain MRI (cerebral edema, microbleeding, etc.)
Evaluate the Safety, Tolerability and Pharmacodynamics of Intravenous Administration of
 SHR-1707 In Patients with Mild Cognitive Impairment Due to Alzheimer's Disease or Mild
 Alzheimer's Disease.
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT05681819
- Type
- Non-Device Trial
Access comprehensive clinical trial information for NCT05681819 through Pure Global AI's free database. This Phase 1 trial is sponsored by Shanghai Hengrui Pharmaceutical Co., Ltd. and is currently Not yet recruiting. The study focuses on Alzheimer's Disease. Target enrollment is 41 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.